drugset / Trial / NCT07671339
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1
Recruiting
20 enrolled
Memorial Sloan Kettering Cancer Center
BeOne Medicines · collabBreak Through Cancer · collabElicio Therapeutics · collabLustgarten Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.
Timeline
- Start
- 2026-06-22
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ELI-002 7P | Vaccine | — | Subcutaneous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |